Board summary
Key figures
48,708
Registered population
60.4% aged 18–64
14.6%
Aged 65+
ICB 19.9% · England 17.9%
27.1%
Ethnic minority (non-White)
12.2% Asian · England 9.6%
29.4%
In IMD quintile 1
ICB 17.1% · England 21.0%
~12,842
Core20 residents (est.)
Resident basis; registered basis ~14,755 · see page 3
6,481
Hypertension register
+6.96% in 3 yrs · England +5.60%
352
SMI register
38.1% of Gravesham's
842
COPD register
Reviews -0.90% in 3 yrs
Forecast to 2030
7,670
Hypertension patients, 2030
+1,189 on today
64.5%
QRISK ≥20% on statins, 2030
+2.55pp over 3 yrs
3.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail local and national benchmarks.
Annual reviews reached 54.9% (Gravesham 58.5%, England 65.7%), a 1,044 scale gap across 2,315 patients that may reflect recall bottlenecks to test locally.
Heart failure and hypertension monitoring fell since 2023.
From 2023 to 2025, heart failure reviews changed -17.2% (England +8.7%) to 63.6% and hypertension BP checks changed -2.9% (England +3.6%) to 82.0%.
Diabetes statin prescribing and psychosis checks outpaced England.
Over 2023 to 2025, statin prescribing in diabetes without CVD grew +9.2% (England +2.1%) to 73.7%, and psychosis alcohol recording rose +15.2 pp.
Population, age and ethnicity
Registered patients include 25.1% aged 0-17 and 27.1% non-White residents, exceeding national shares
Gravesend Alliance PCN serves 48,708 registered patients, with 25.1% (12,203) aged 0-17, above Gravesham (22.1%), NHS Kent and Medway ICB (20.7%) and England (19.6%). Conversely, 14.6% (7,110) are aged 65+, below Gravesham (16.2%), the ICB (19.9%) and England (17.9%). Census usual residents in PCN-associated areas are 27.1% non-White, including 12.2% Asian / Asian British and 8.7% Black / African / Caribbean / Black British, compared to Gravesham (11.2%, 6.5%), the ICB (4.7%, 3.1%) and England (9.6%, 4.2%).
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Gravesham local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Gravesham LA) | 2,011 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 71.1% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 50.1% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Gravesham LA) | 1,055 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Gravesham LA) | 13.1 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 29.4% and varies by 17.9 percentage points across practices
The PCN Core20 cohort comprises 29.4% of registered patients, above Gravesham (25.0%), NHS Kent and Medway ICB (17.1%) and England (21.0%). Deprivation is uneven across member practices, spanning a 17.9 pp range from The Shrubbery Surgery (19.9%) to Oakfield Health Centre, Practice 2 (37.8%). Springhead Health holds the largest volume with 7,565 estimated Core20 patients (35.0%). A 0.92 pp reconciliation gap separates the PCN rate from the 30.3% weighted practice share. Outreach planning could balance practice concentration against casework volume.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
352
SMI register
0.71% recorded prevalence
333
Learning disability register
0.67% recorded prevalence
15
Care homes, 591 beds
In the PCN catchment
9.3%
Provide unpaid care
Gravesham, Census 2021
The PCN registers 352 severe mental illness patients (0.7% vs England 1.0%) and 333 learning disability patients (0.7% vs England 0.6%), alongside 15 catchment care homes (591 beds). Borough-level data records 8 rough sleepers in Gravesham in 2025. Crude register prevalence and catchment bed capacity do not establish resident registrations or unmet need, which primary care record audits would need to evaluate.
Severe mental illness: physical health checks
SMI blood pressure checks reached 75.2% (England 83.4%), with Springhead Health at 71.0%, while BMI checks reached 73.9% (England 82.1%). Both physical health check elements trail national benchmarks across member practices.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,481
Hypertension register
+6.96%
Register growth, 3 yrs
Gravesham +4.52% · England +5.60%
+0.39pp
BP control, under 80
≤140/90 · +1.31pp aged 80+
+1,189
More patients by 2030
Forecast 7,670 (15.00%)
Hypertension case-finding and control
Hypertension prevalence is 13.1% (6,481 patients), below Gravesham (14.1%), NHS Kent and Medway ICB (16.2%), and England (15.2%), though unadjusted rates do not confirm under-detection (+396 to +937 benchmark range). For registered patients, recent blood pressure recording fell 2.9% over 2023 to 2025 (England +3.6%) to 82.0% (England 90.0%). Treatment to target stands at 62.7% (England 70.3%), and blood pressure <= 140/90 mmHg in patients under 80 is 59.5% (England 67.8%). Routine blood pressure monitoring and control trail national benchmarks, so clinical teams should prioritise recalling hypertensive patients whose readings are missing or above threshold.
Lipids and statins
Among patients with QRISK >= 20%, 59.1% receive lipid-lowering therapy, below England (63.6%) and NHS Kent and Medway ICB (61.4%) though above Gravesham (58.9%). Statin coverage in chronic kidney disease is 66.1% (England 70.3%). Lower uptake in QRISK >= 20% and CKD cohorts indicates scope to review treatment coverage.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 68,672 | £2.10 | £1.90 | £1.86 | £144,211 |
| Cardiovascular (all), 2025 | 94,766 | £3.73 | £3.57 | £3.33 | £353,477 |
In 2026, 68,672 lipid-regulating drug items were prescribed at £2.10 per item, above Gravesham (£1.61), NHS Kent and Medway ICB (£1.90), and England (£1.86), representing £16,481 more than at England's unit cost. Higher unit spend suggests scope to audit formulary choices alongside clinical targets.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+5.16%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.60%
Asthma prevalence, PCN 3-yr % change
Asthma annual reviews reached 54.9%, trailing Gravesham (58.5%), NHS Kent and Medway ICB (60.4%) and England (65.7%), indicating an unreviewed scale gap of 1,044 patients across the 2,315 register. Reviews span from 45.2% at Oakfield Health Centre, Practice 2 to 63.8% at Springhead Health. Meanwhile, across 842 COPD patients, review completion was 69.8% (England 76.4%), with a three-year change of -0.9% over 2023 to 2025 (England +2.8%).
Cancer register and children's immunisation
Cancer prevalence is 2.9% (England 3.8%) across 1,452 registered patients. In Q1 2025/26, 6-in-1 coverage at 12 months was 87.9% (England 91.0%, target 95%). At age 5, Gravesend Alliance PCN achieved 94.1% MMR dose 1 coverage and 85.0% MMR dose 2 coverage, reflecting a 9.1 pp same-cohort difference. At The Shrubbery Surgery, the same-cohort difference between first and second dose was 13.6 pp.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
Across NHS Kent and Medway ICB in 2022, 55.6% of staged cancers were diagnosed at stage 1 or 2 (England 55.3%), 19.4 pp below the 75.0% national ambition, with 1,627 extra early-stage cases required. Staging was known for 63.6% of cases (England 67.0%). Within primary care screening, PCN cervical coverage (25-49 yrs) was 66.5% (ICB 69.9%), varying from 60.8% at Springhead Health to 70.2% at The Shrubbery Surgery and 75.1% at Oakfield Health Centre, Practice 2, alongside breast screening coverage of 63.4% (England 69.9%). Targeted uptake initiatives at practices below benchmarks could reduce missed early detection opportunities.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Dartford and Gravesham NHS Trust achieved 63.6% on the 62-day cancer referral to treatment standard (standard 85.0%), trailing Medway NHS Foundation Trust (81.6%), NHS Kent and Medway Integrated Care Board (75.9%), and England (71.2%). On the 28-day faster diagnosis standard, Dartford and Gravesham NHS Trust reached 78.1% (Medway NHS Foundation Trust 77.8%, ICB 76.8%, England 79.3%), exceeding the 75.0% standard. Diagnostic 6-week waits stood at 8.4% at Dartford and Gravesham NHS Trust, compared with Medway NHS Foundation Trust (14.2%), Kent Community Health NHS Foundation Trust (27.5%), and England (23.1%).
| Pathways within standard (%) | Dartford and Gravesham | Medway | Kent and Medway ICB | England |
|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 78.14 | 77.77 | 76.78 | 79.32 |
| 31-day treatment (96%) | 97.48 | 99.62 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 63.59 | 81.64 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Dartford and Gravesham | Kent Health | Medway | England |
|---|---|---|---|---|
| MRI | 0.36 | — | 0.68 | 21.40 |
| CT | 2.08 | — | 0.00 | 9.92 |
| Echocardiography | 3.90 | — | 36.62 | 28.48 |
| Colonoscopy | 0.40 | — | 1.88 | 30.83 |
| Gastroscopy | 0.00 | — | 3.32 | 29.02 |
| All 15 DM01 tests | 8.37 | 27.49 | 14.20 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). For Jun 2026 (provisional), experimental community data records 210,170 care contacts across Kent (60,605 patients with a contact) and 254,055 contacts across NHS Kent and Medway Integrated Care Board. Community care activities reached 265,905 in Kent and 297,595 for the ICB. In Kent, contacts with adults aged 65+ accounted for 65.8% of contacts. These figures reflect local authority and system activity rather than PCN-specific patient flows.
Practice variation and patient experience
Phone access varies by 49.5 pp across practices, which could reflect uneven demand
In 2025/26, overall QOF achievement ranged from 85.8% at Oakfield Health Centre, Practice 2 to 89.5% at The Shrubbery Surgery (England 92.5%). Clinical achievement reached 98.8% at The Shrubbery Surgery. Vaccination and immunisation lagged England (55.2%) at captured practices, from 15.6% at The Shrubbery Surgery to 24.9% at Oakfield Health Centre, Practice 2 (a 9.3 pp spread).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Shrubbery | 73 | 19.9 | 68.1% | 60.5% | 78.6% |
| Springhead Health | 102 | 35.0 | 18.6% | 63.5% | 68.2% |
| Oakfield , 2 | 94 | 37.8 | 52.1% | 73.2% | 66.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Ten clinical measures trail England's three-year change led by heart failure reviews
Across 2023 to 2025, ten measures trail England's three-year change. Heart failure reviews changed -17.2% (England +8.7%) to 63.6% (England 78.5%), hypertension blood pressure checks changed -2.9% (England +3.6%) to 82.0% (England 90.0%), and smoking cessation offers changed -6.2 pp (England +0.1 pp). Strengths include alcohol recording in psychosis (+15.2 pp vs England +5.4 pp), diabetes statin therapy (+9.2% vs England +2.1%), and mental health BMI checks (+9.6 pp vs England +5.1 pp). Lagging review rates could reflect recall bottlenecks that local audit should evaluate.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Hypertension BP reading
Smoking support (SMI)
COPD reviews
Hypertension treated to target
Alcohol record (psychosis)
Diabetes statin (no CVD)
BMI record (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Gravesham | Asset | PCN | Gravesham |
|---|---|---|---|---|---|
| Care homes (catchment) | 15 (591 beds) | n/a | Schools (catchment) | 81 | n/a |
| Children's centres | 6 | 5 | Places of worship | 33 | 46 |
| Libraries | 6 | 8 | Food banks (VCS) | 1 | 1 |
| Day centres (VCS) | 9 | 13 | Children and young people (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 2 | Primary schools (LA maintained) | 12 | 16 |
| Primary academies | 14 | 16 | Special schools | 3 | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma annual reviews reached 54.9% (Gravesham 58.5%, ICB 60.4%, England 65.7%), leaving a 1,044-patient scale gap across the 2,315 register (45.2% at Oakfield Health Centre, Practice 2). For discussion: the PCN could test a standardised asthma recall template with after-school and flexible clinic slots, reviewing inhaler prescribing alongside annual reviews. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension BP monitoring and recall
Hypertension prevalence is 13.1% (6,481 patients; +396 to +937 benchmark range vs Gravesham 14.1% and England 15.2%); recent BP checks fell 2.9% (2023 to 2025) to 82.0% (England 90.0%) and control is 59.5% (England 67.8%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Long-term condition and SMI review audit
Over 2023 to 2025, heart failure reviews (396 register) fell 17.2% to 63.6% (England 78.5%) and COPD reviews (842 register) fell 0.9% to 69.8% (England 76.4%); SMI BP checks (352 register) reached 75.2% (England 83.4%). Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric and diverse community outreach (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Dual-track Core20 resource allocation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster catch-up outreach (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Core20 cohort (IMD quintile 1) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Hypertension BP monitoring and recall (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · Long-term condition and SMI review audit (p12) | Heart failure register · Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) · COPD register | MHIS · From Harm to Hope | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
